Agomab

agomab.com

AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that can potentially restore organ function in patients with fibrotic, inflammatory, autoimmune, and degenerative diseases. The company is focusing on biologically validated pathways, such as Transforming Growth Factor β and Hepatocyte Growth Factor, and leveraging specialized capabilities in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline across multiple fibrotic conditions, end-to-end research and development expertise, a successful business development track record, and a robust investor base.